Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
0700
The dude/dudress is like those street dogs shirting all over the place. Probably paid to shirt shirts things here. Down the toilet in a nice swirl...usssshhhhhh...pluff.
Enjoy the sun, people. See you on monday at 0800.
St
Flyinhigh81, wow.
So desperate to post the link you had to do it twice? Only 11 post during all your membership on lse? All avct?
Highly suspicious to me. Filtered.
ST
Youâre welcome, I posted if first. Iâll have to remember to include a headline grabbing statement next time. Perhaps my career in marketing needs more work...
Anyway, I agree that Cyvita will want to give Avacta priority. I think thereâs maybe a bit of a hedge with their involvement with Sona, or alternatively theyâd signed up with Sona and then realised the improved potential with Avacta. You can tell by the language Cyvita use (==screening) that they know Avactaâs product is the test that can help globally and in huge volume
Thanks for posting that flyinghigh81, we should be using our energy to look over our shoulders..
âItâs in the bag for them:â
I will try to be objective but I cannot evidence these thoughts as not all the info is in the public domain for obvious commercial reasons.
I think Sona could well beat us to it, insofar as getting FDA first. Now hereâs the but. It depends on what AVCT release next week. AS has so far over delivered. There may or may not be relevance in my earlier post about the deduction that Sona have gone elsewhere for FDA (thanks RorkesDrift for your thoughtful assistance with our thinking) . It could be that AS has grabbed the resources to be first and Sona didnât want to wait so went to Global. We donât know but add that to Cytivaâs concerns around temperature tolerances with LFT it may be that they have gone for a âsofter optionâ. There has been quite a bit of strange info and I could be miss interpreting it but the rationale deduction is Sona are not allowing Cytiva to do FDA. Why.
I think Cytiva have prioritised AVCT LFT. They intimated that the Sona test was better suited to lab. (See my earlier posts for links). There are also two other critical factors at play here...
1. scalability. We donât know how scalable the Sona test is, all they have said itâs antigen based. What does that mean? However, we do know (youâd have seen the vid) that the avct bead affimer tech based on a protein can be upscaled and mass produced and is stable at room temperatures, transportable etc. (We donât know the definition of room temp though)
2. Costs. Sona use gold in in their nanorods to overcome the CTAB issues, that introduces a high cost uncontrollable element hence their test will initially retail at a little under $50 a test. That imo is too expensive for a mass population at home test. It would also add too much to airport flight tickets etc. You get the gist. AVCT test is not dependent on price of gold so there are more benefits from economies of scale and it can be mass produced and produce under licence. So an edge. But if they price it at $25 that is still imo too expensive. Sure itâll be dear initially but to attract volume and build market entry barriers price is key. AS will know this.
So say Sona cross the line first. Donât underestimate first mover advantage, itâs massive. They will land big contracts. Whether they can scale up and reduce price I donât know. But if they do and they have a reliable product (Remember itâs only so far been lab tested in April) then there will be no customer allegiances if there is an equivalent or better product available at half the price with a shorter delivery lead time.
Now for Goldilocks, should avct deliver FDA before Sona. Bye bye Sona. No first mover advantage and too expensive. Avct can then keep pushing the price down and driving volume. Exclusivity, patent protected.
As for SP if Sona get fda first expect a hit but if avct follow boom, and price will prevail.
Gl to them I would rather take a saliva one than a nasal swab though!
How so FH81?
Itâs in the bag for them:
https://bondhealth.co.uk/blog/lateral-flow-a-technology-whose-time-has-come